Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Fig. 4

a Tumor growth in mice before and after injection of DOTATATE in control animals (4 × 0.3 nmol DOTATATE) and 213Bi-DOTATATE at different concentration, in low-dose cohort (16.8 ± 1.3 MBq) and high-dose cohort (33.1 ± 3.7 MBq). Treatment started 23 days after inoculation of AR42J cells. The solid line indicates the extrapolated fit calculated for tumor growth, and dotted lines indicate the 95% confidence interval for the fit. b Survival of AR42J-bearing animals after 213Bi-DOTATATE therapy. Low-dose animals received 16.8 ± 1.3 MBq 213Bi-DOTATATE, high-dose 33.1 ± 3.7 MBq, and control 4 × 0.3 nmol DOTATATE on 2 consecutive days

Back to article page